{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:31:00Z","timestamp":1765888260112,"version":"3.37.3"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1124\/dmd.119.089052","type":"journal-article","created":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T01:35:22Z","timestamp":1577756122000},"page":"169-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Influence of Uridine Diphosphate Glucuronosyltransferase Family 1 Member A1 and Solute Carrier Organic Anion Transporter Family 1 Member B1 Polymorphisms and Efavirenz on Bilirubin Disposition in Healthy Volunteers"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4978-4593","authenticated-orcid":false,"given":"Kimberly S.","family":"Collins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid F.","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon T.","family":"Gufford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica B.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth B.","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria M.","family":"Pratt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd C.","family":"Skaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeruesenay","family":"Desta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.119.089052_bib1","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/03602530802341133","article-title":"Drug-induced hyperbilirubinemia and the clinical influencing factors","volume":"40","author":"Ah","year":"2008","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.119.089052_bib2","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3389\/fgene.2019.01073","article-title":"Combined effects of UGT1A1 and SLCO1B1 variants on Chinese adult mild unconjugated hyperbilirubinemia","volume":"10","author":"Bai","year":"2019","journal-title":"Front Genet"},{"key":"10.1124\/dmd.119.089052_bib3","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM199511023331802","article-title":"The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert\u2019s syndrome","volume":"333","author":"Bosma","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.119.089052_bib4","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1046\/j.1440-1746.1999.01984.x","article-title":"Molecular genetic basis of Gilbert\u2019s syndrome","volume":"14","author":"Burchell","year":"1999","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1124\/dmd.119.089052_bib5","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/cpt.892","article-title":"Variants in the CYP2B6 3\u2019UTR alter in vitro and in vivo CYP2B6 activity: potential role of MicroRNAs","volume":"104","author":"Burgess","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.089052_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/ahg.12179","article-title":"Genetic variations in bilirubin metabolism genes and their association with unconjugated hyperbilirubinemia in adults","volume":"81","author":"Chiddarwar","year":"2017","journal-title":"Ann Hum Genet"},{"key":"10.1124\/dmd.119.089052_bib7","doi-asserted-by":"crossref","first-page":"16943","DOI":"10.1016\/S0021-9258(18)41876-5","article-title":"Hepatic microsomal bilirubin UDP-glucuronosyltransferase. The kinetics of bilirubin mono- and diglucuronide synthesis","volume":"267","author":"Crawford","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.119.089052_bib8","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/hiv.12368","article-title":"Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir- vs. efavirenz-based antiretroviral therapy","volume":"17","author":"Estrada","year":"2016","journal-title":"HIV Med"},{"key":"10.1124\/dmd.119.089052_bib9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/cpt.269","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for UGT1A1 and atazanavir prescribing","volume":"99","author":"Gammal","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.089052_bib10","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/01.qai.0000167156.44980.33","article-title":"Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study","volume":"39","author":"Gerber","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1124\/dmd.119.089052_bib11","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1056\/NEJMoa031772","article-title":"Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection","volume":"350","author":"Gulick","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.119.089052_bib12","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jhep.2018.12.038","article-title":"Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis","volume":"70","author":"Gwag","year":"2019","journal-title":"J Hepatol"},{"key":"10.1124\/dmd.119.089052_bib13","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.atherosclerosis.2012.06.002","article-title":"Effects of statin treatments and polymorphisms in UGT1A1 and SLCO1B1 on serum bilirubin levels in Chinese patients with hypercholesterolaemia","volume":"223","author":"Hu","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1124\/dmd.119.089052_bib14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/01.pdm.0000213467.91139.c9","article-title":"Validation of rapid polymerase chain reaction-based detection of all length polymorphisms in the UGT 1A1 gene promoter","volume":"16","author":"Huang","year":"2007","journal-title":"Diagn Mol Pathol"},{"key":"10.1124\/dmd.119.089052_bib15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1042\/bj3270305","article-title":"ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2","volume":"327","author":"Jedlitschky","year":"1997","journal-title":"Biochem J"},{"key":"10.1124\/dmd.119.089052_bib16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/1098-1004(200010)16:4<297::AID-HUMU2>3.0.CO;2-Z","article-title":"Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype","volume":"16","author":"Kadakol","year":"2000","journal-title":"Hum Mutat"},{"key":"10.1124\/dmd.119.089052_bib17","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1124\/dmd.113.055772","article-title":"The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia","volume":"42","author":"Keppler","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.089052_bib18","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/clpt.2011.276","article-title":"Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics","volume":"91","author":"Kharasch","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.089052_bib19","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1097\/QAD.0000000000001594","article-title":"Cardiovascular outcomes among HIV-infected veterans receiving atazanavir","volume":"31","author":"LaFleur","year":"2017","journal-title":"AIDS"},{"key":"10.1124\/dmd.119.089052_bib20","doi-asserted-by":"crossref","first-page":"559","DOI":"10.47102\/annals-acadmedsg.V41N12p559","article-title":"Unexpected drug-drug interactions in human immunodeficiency virus (HIV) therapy: induction of UGT1A1 and bile efflux transporters by Efavirenz","volume":"41","author":"Lee","year":"2012","journal-title":"Ann Acad Med Singapore"},{"key":"10.1124\/dmd.119.089052_bib21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/cr.2009.33","article-title":"A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http:\/\/analysis.bio-x.cn)","volume":"19","author":"Li","year":"2009","journal-title":"Cell Res"},{"key":"10.1124\/dmd.119.089052_bib22","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1161\/CIRCULATIONAHA.106.633206","article-title":"Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study","volume":"114","author":"Lin","year":"2006","journal-title":"Circulation"},{"key":"10.1124\/dmd.119.089052_bib23","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/QAI.0000000000000333","article-title":"Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir\/ritonavir","volume":"67","author":"Malvestutto","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1124\/dmd.119.089052_bib24","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1124\/jpet.116.232876","article-title":"Chiral plasma pharmacokinetics and urinary excretion of bupropion and metabolites in healthy volunteers","volume":"358","author":"Masters","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.119.089052_bib25","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.curtheres.2014.05.002","article-title":"Substantial effect of efavirenz monotherapy on bilirubin levels in healthy volunteers","volume":"76","author":"Metzger","year":"2014","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1124\/dmd.119.089052_bib26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/clpt.2012.34","article-title":"Compartment-specific gene regulation of the CAR inducer efavirenz in vivo [published correction appears in Clin Pharmacol Ther 93:129]","volume":"92","author":"Meyer zu Schwabedissen","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.089052_bib27","first-page":"805","article-title":"Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs","volume":"72","author":"Molt\u00f3","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/dmd.119.089052_bib28","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.119.089052_bib29","doi-asserted-by":"crossref","unstructured":"Robarge JD, Metzger IF, Lu J, Thong N, Skaar TC, Desta Z, Bies RR (2016) Population pharmacokinetic modeling to estimate the contributions of genetic and nongenetic factors to efavirenz disposition. Antimicrob Agents Chemother 61.","DOI":"10.1128\/AAC.01813-16"},{"key":"10.1124\/dmd.119.089052_bib30","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1086\/466531","article-title":"Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia","volume":"192","author":"Rotger","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1124\/dmd.119.089052_bib31","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.dmpk.2016.06.001","article-title":"Gene-gene interactions between DRD3, MRP4 and CYP2B6 polymorphisms and its influence on the pharmacokinetic parameters of efavirenz in HIV infected patients","volume":"31","author":"S\u00e1nchez-Mart\u00edn","year":"2016","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.119.089052_bib32","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.bcp.2013.04.002","article-title":"Agonism of human pregnane X receptor by rilpivirine and etravirine: comparison with first generation non-nucleoside reverse transcriptase inhibitors","volume":"85","author":"Sharma","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.119.089052_bib33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.cr.7290272","article-title":"SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci","volume":"15","author":"Shi","year":"2005","journal-title":"Cell Res"},{"key":"10.1124\/dmd.119.089052_bib34","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00228-014-1732-8","article-title":"Effects of enzyme inducers efavirenz and tipranavir\/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir","volume":"70","author":"Song","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.119.089052_bib35","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1056\/NEJM199912163412501","article-title":"Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team","volume":"341","author":"Staszewski","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.119.089052_bib36","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.3748\/wjg.v19.i38.6398","article-title":"New insights in bilirubin metabolism and their clinical implications","volume":"19","author":"Sticova","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1124\/dmd.119.089052_bib37","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1172\/JCI59526","article-title":"Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver","volume":"122","author":"van de Steeg","year":"2012","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1124\/dmd.119.089052_bibib42","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0021-9150(01)00601-3","article-title":"Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels","volume":"160","author":"V\u00edtek","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.1124\/dmd.119.089052_bib38","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1097\/QAD.0000000000001845","article-title":"The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?","volume":"32","author":"Vitoria","year":"2018","journal-title":"AIDS"},{"key":"10.1124\/dmd.119.089052_bib39","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1254\/jphs.08209FP","article-title":"Induction of multiple drug transporters by efavirenz","volume":"109","author":"Weiss","year":"2009","journal-title":"J Pharmacol Sci"},{"key":"10.1124\/dmd.119.089052_bib40","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/clpt.2012.57","article-title":"The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy","volume":"92","author":"Wilke","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10.1124\/dmd.119.089052_bibib41","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/j.1440-1681.2007.04798.x","article-title":"OATP1B1 polymorphism is a major determinant of serum bilirubin level but not associated with rifampicin-mediated bilirubin elevation","volume":"34","author":"Zhang","year":"2007","journal-title":"Clin Exp Pharmacol Physiol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562407747X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562407747X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.119.089052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:19:41Z","timestamp":1739956781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009095562407747X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S009095562407747X"],"URL":"https:\/\/doi.org\/10.1124\/dmd.119.089052","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of Uridine Diphosphate Glucuronosyltransferase Family 1 Member A1 and Solute Carrier Organic Anion Transporter Family 1 Member B1 Polymorphisms and Efavirenz on Bilirubin Disposition in Healthy Volunteers","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.119.089052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}